来自官方财务报表的收入、利润与现金流历史。
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| 总收入 | JPY 825.4B | JPY 789.4B | JPY 741.8B | JPY 744.4B |
| 毛利 | JPY 634.2B | JPY 620.6B | JPY 586.4B | JPY 566.6B |
| 营业利润（EBIT） | JPY 44.1B | JPY 54.4B | JPY 53.4B | JPY 40.0B |
| 净利 | JPY 38.6B | JPY 46.4B | JPY 42.4B | JPY 55.4B |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 4523 交互式查看器。 /companies/us/4523
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms